IL166431A0 - Microcapsules with modified release of active principles with low solubility for oral delivery - Google Patents

Microcapsules with modified release of active principles with low solubility for oral delivery

Info

Publication number
IL166431A0
IL166431A0 IL16643105A IL16643105A IL166431A0 IL 166431 A0 IL166431 A0 IL 166431A0 IL 16643105 A IL16643105 A IL 16643105A IL 16643105 A IL16643105 A IL 16643105A IL 166431 A0 IL166431 A0 IL 166431A0
Authority
IL
Israel
Prior art keywords
microcapsules
low solubility
modified release
oral delivery
active principles
Prior art date
Application number
IL16643105A
Other languages
English (en)
Original Assignee
Flamel Tech Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flamel Tech Sa filed Critical Flamel Tech Sa
Publication of IL166431A0 publication Critical patent/IL166431A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL16643105A 2002-07-26 2005-01-20 Microcapsules with modified release of active principles with low solubility for oral delivery IL166431A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0209530A FR2842735B1 (fr) 2002-07-26 2002-07-26 Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os
PCT/FR2003/002384 WO2004010984A2 (fr) 2002-07-26 2003-07-28 Microcapsules a liberation modifiee de principes actifs peu solubles pour administration per os

Publications (1)

Publication Number Publication Date
IL166431A0 true IL166431A0 (en) 2006-01-15

Family

ID=30011527

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16643105A IL166431A0 (en) 2002-07-26 2005-01-20 Microcapsules with modified release of active principles with low solubility for oral delivery

Country Status (13)

Country Link
US (2) US20060275376A1 (de)
EP (2) EP1524969A2 (de)
JP (1) JP2005535680A (de)
KR (1) KR20050026518A (de)
CN (1) CN1681483B (de)
AU (1) AU2003269068B2 (de)
BR (1) BR0312988A (de)
CA (1) CA2493464C (de)
FR (1) FR2842735B1 (de)
IL (1) IL166431A0 (de)
MX (1) MXPA05001076A (de)
WO (1) WO2004010984A2 (de)
ZA (1) ZA200500734B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
PT1492511E (pt) 2002-04-09 2009-04-09 Flamel Tech Sa Formulação farmacêutica oral na forma de suspensão aquosa de microcápsulas para libertação modificada de princípio(s) activo(s)
FR2869624B1 (fr) * 2004-04-28 2006-06-09 Inst Francais Du Petrole Structure et revetement auto-reparables pour milieu corrosif
FR2869764B1 (fr) * 2004-05-07 2006-07-21 Olivier Roche Complement nutrionnel liquide et procede de preparation de ce complement
FR2881652B1 (fr) * 2005-02-08 2007-05-25 Flamel Technologies Sa Forme pharmaceutique orale microparticulaire anti-mesuage
CA2598410A1 (fr) * 2005-02-21 2006-08-24 Flamel Technologies Forme pharmaceutique orale de losartan
FR2885526B1 (fr) * 2005-05-13 2007-07-27 Flamel Technologies Sa Medicament oral a base d'inhibiteur de pompe a protons
FR2886150B1 (fr) * 2005-05-24 2007-08-24 Flamel Technologies Sa Forme pharmaceutique orale a base d'au moins un principe actif dont la solubilite varie en fonction des conditions de ph gastrique
WO2006133733A1 (en) 2005-06-13 2006-12-21 Flamel Technologies Oral dosage form comprising an antimisuse system
US8652529B2 (en) 2005-11-10 2014-02-18 Flamel Technologies Anti-misuse microparticulate oral pharmaceutical form
AU2009301994B2 (en) 2008-10-08 2016-10-20 Bioplus Life Sciences Pvt. Ltd. Sustained release drug delivery system
FR2945947B1 (fr) 2009-05-29 2011-07-29 Flamel Tech Sa Compositions pharmaceutiques flottantes a liberation controlee
FR2945945B1 (fr) 2009-05-29 2011-07-29 Flamel Tech Sa Procede de preparation de particules creuses et leurs applications
HUE042593T2 (hu) * 2010-03-09 2019-07-29 Alkermes Pharma Ireland Ltd Alkoholnak ellenálló enterális gyógyszerkészítmények
GB2479213B (en) 2010-04-01 2013-07-10 Theravida Inc Pharmaceutical formulations for the treatment of overactive bladder
WO2012120366A1 (en) * 2011-03-09 2012-09-13 Ideal Cures Pvt. Ltd. Novel moisture barrier immediate release film coating composition
KR101811301B1 (ko) 2011-05-24 2017-12-26 삼성전자주식회사 반도체 패키지
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
AU2013350329A1 (en) * 2012-11-26 2015-07-02 Progel Pty Ltd Coating composition
DK2925300T6 (da) 2012-11-29 2021-02-08 Progel Pty Ltd Mikropartikler omfattende et probiotikum, et reagens, der kan tværbindes, et denatureret protein, et polyolplastificeringsmiddel og trehalose
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US9233204B2 (en) 2014-01-31 2016-01-12 Aseko, Inc. Insulin management
EA033900B1 (ru) 2014-02-21 2019-12-06 Принсипиа Биофарма Инк. СОЛЕВЫЕ И АМОРФНЫЕ ФОРМЫ 2-[(3R)-3-[4-АМИНО-3-(2-ФТОР-4-ФЕНОКСИФЕНИЛ)ПИРАЗОЛО[3,4-d]ПИРИМИДИН-1-ИЛ]ПИПЕРИДИН-1-КАРБОНИЛ]-4-МЕТИЛ-4-[4-(ОКСЕТАН-3-ИЛ)ПИПЕРАЗИН-1-ИЛ]ПЕНТ-2-ЕННИТРИЛА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ПУЗЫРЧАТКИ ОБЫКНОВЕННОЙ И ПУЗЫРЧАТКИ ЛИСТОВИДНОЙ С ИХ ПРИМЕНЕНИЕМ
WO2016069475A1 (en) 2014-10-27 2016-05-06 Aseko, Inc. Subcutaneous outpatient management
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
EA036269B1 (ru) 2014-12-18 2020-10-21 Принсипиа Биофарма Инк. Лечение пузырчатки
BR112017013728A2 (pt) * 2014-12-24 2018-03-13 Principia Biopharma Inc. dosagem de inibidor da btk a sítio específico
US20180305350A1 (en) 2015-06-24 2018-10-25 Principia Biopharma Inc. Tyrosine kinase inhibitors
US9886556B2 (en) 2015-08-20 2018-02-06 Aseko, Inc. Diabetes management therapy advisor
CN108697688A (zh) 2016-01-20 2018-10-23 塞拉维达公司 用于治疗多汗症的方法和组合物
CN105581996B (zh) * 2016-02-23 2018-03-27 广西梧州制药（集团）股份有限公司 一种去水卫矛醇微囊及其制备方法
US20190231784A1 (en) 2016-06-29 2019-08-01 Principia Biopharma Inc. Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
JP2022522270A (ja) 2019-03-01 2022-04-15 フラメル アイルランド リミテッド 食事摂取状態における改善された薬物動態を有するガンマ－ヒドロキシ酪酸塩組成物
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2313915A1 (fr) * 1976-01-26 1977-01-07 Corneille Gilbert Nouvelle forme galenique d'administration de la vincamine et de ses derives, son procede de preparation et medicaments comprenant cette nouvelle forme
US4321253A (en) * 1980-08-22 1982-03-23 Beatty Morgan L Suspension of microencapsulated bacampicillin acid addition salt for oral, especially pediatric, administration
HU187215B (en) * 1983-01-26 1985-11-28 Egyt Gyogyszervegyeszeti Gyar Method for producing pharmaceutical product of high actor content and prolonged effect
LU85943A1 (fr) * 1985-06-12 1987-01-13 Galephar Comprimes pharmaceutiques permettant l'administration aisee de pellets, leur preparation et leur utilisation
JPH0236571B2 (ja) 1986-04-11 1990-08-17 Otsuka Pharma Co Ltd Jizokuseiseizai
SE8601624D0 (sv) 1986-04-11 1986-04-11 Haessle Ab New pharmaceutical preparations
GB8705083D0 (en) 1987-03-04 1987-04-08 Euro Celtique Sa Spheroids
SE509029C2 (sv) 1988-08-16 1998-11-30 Ss Pharmaceutical Co Långtidsverkande diklofenak-natriumpreparat
IT1227899B (it) * 1988-12-23 1991-05-14 Poli Ind Chimica Spa Rivestimento totale o parziale di principi attivi farmaceutici e relative composizioni
US5084278A (en) * 1989-06-02 1992-01-28 Nortec Development Associates, Inc. Taste-masked pharmaceutical compositions
GB8913889D0 (en) 1989-06-16 1989-08-02 May & Baker Ltd New compositions of matter
US5500227A (en) 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
JPH0873345A (ja) 1994-09-05 1996-03-19 Terumo Corp 医薬製剤
FR2725623A1 (fr) * 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
FR2732218B1 (fr) * 1995-03-28 1997-08-01 Flamel Tech Sa Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s) et leurs procedes de preparation
WO1998026803A1 (fr) 1996-12-19 1998-06-25 Daiichi Pharmaceutical Co., Ltd. Composition pharmaceutique pour administration par voie orale
US5965167A (en) 1997-10-07 1999-10-12 Sanghvi; Pradeepkumar P. Dosage units
IL162023A0 (en) 1998-03-30 2005-11-20 Rtp Pharma Inc Compositions containing microparticles of water-insoluble substances and method for their preparation
CA2346001C (en) 1998-10-01 2003-12-30 Elan Pharma International, Limited Controlled release nanoparticulate compositions
HUP0104778A3 (en) 1998-12-24 2004-05-28 Janssen Pharmaceutica Nv Controlled release galantamine composition
FR2816840B1 (fr) 2000-11-17 2004-04-09 Flamel Tech Sa Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
EP1385486A4 (de) * 2001-04-18 2006-05-17 Nostrum Pharmaceuticals Inc Neuartiger überzug für eine pharmazeutische zusammensetzung mit verzögerter freisetzung
FR2825023B1 (fr) * 2001-05-23 2005-04-15 Flamel Tech Sa Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
FR2837100B1 (fr) * 2002-03-18 2004-07-23 Flamel Tech Sa Comprimes a bases de microcapsules a liberation modifiee
CA2480824A1 (fr) * 2002-04-09 2003-10-16 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee d'amoxicilline
PT1492511E (pt) * 2002-04-09 2009-04-09 Flamel Tech Sa Formulação farmacêutica oral na forma de suspensão aquosa de microcápsulas para libertação modificada de princípio(s) activo(s)
WO2012035074A1 (en) * 2010-09-14 2012-03-22 Nanologica Ab Super-saturating delivery vehicles for poorly water-soluble pharmaceutical and cosmetic active ingredients

Also Published As

Publication number Publication date
CN1681483B (zh) 2011-12-28
EP2272506A3 (de) 2013-07-10
KR20050026518A (ko) 2005-03-15
CA2493464C (fr) 2012-07-03
AU2003269068A1 (en) 2004-02-16
FR2842735B1 (fr) 2006-01-06
EP2272506A2 (de) 2011-01-12
US20070160678A1 (en) 2007-07-12
MXPA05001076A (es) 2005-06-06
FR2842735A1 (fr) 2004-01-30
BR0312988A (pt) 2005-06-21
AU2003269068B2 (en) 2009-01-22
CA2493464A1 (fr) 2004-02-05
US20060275376A1 (en) 2006-12-07
EP1524969A2 (de) 2005-04-27
US8821935B2 (en) 2014-09-02
WO2004010984A3 (fr) 2004-04-08
CN1681483A (zh) 2005-10-12
JP2005535680A (ja) 2005-11-24
ZA200500734B (en) 2006-03-29
WO2004010984A2 (fr) 2004-02-05

Similar Documents

Publication Publication Date Title
IL166431A0 (en) Microcapsules with modified release of active principles with low solubility for oral delivery
PL373914A1 (en) Immediate release dosage forms containing solid drug dispersions
EG25542A (en) Oral dosge forms for propiverne or pharmaceutically acceptable salts thereof having prolonged release of the active agent
EP1383376A4 (de) Pharmazeutische formulierungen für die anhaltende wirkstofffreigabe
IL166424A0 (en) Sustained release formulations comprising lamotigine
PL374347A1 (en) Solid pharmaceutical formulations comprising telmisartan
AU2003215334A1 (en) Inhalable formulations for sustained release
HK1085131A1 (en) Solid drug for oral use
TWI319317B (en) Modified release pharmaceutical formulation
HK1089394A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
EP1553925A4 (de) Orale dosierungsform mit modifizierter freisetzung
HK1161123A1 (zh) 含有奧曲肽微顆粒的藥物組合物
AU2003252299A8 (en) Novel physiologically active substance
AU2003232398A1 (en) Sustained release oral dosage forms of gabapentin
AU2003260803A8 (en) Sustained release pharmaceutical composition
IL166337A0 (en) Oral administration of calctionin
EP1564220A4 (de) Retard-arzneistoffträger
AU2003210454A8 (en) Dendritic encapsulation of active agents
IL165069A0 (en) Immediate release pharmaceutical formulation
HK1072194A1 (en) Oral dosage form for controlled drug release
AU2001248336A1 (en) Controlled release oral solid forms containing mesalazine as active agent
EP1478353A4 (de) Pharmazeutische zusammensetzung mit verzögerter freisetzung
GB2392745B (en) Administration of a messaging system
AU2003254672A8 (en) Dual-spike release formulation for oral drug delivery
GB0219897D0 (en) Pharmaceutically active compounds